Company news

iBio, Inc. news in 2025

iBio, Inc.'s news releases, calls and decks from 2025, newest first.

View company

iBio to Participate in the 8th Annual Evercore Healthcare Conference

November 24, 2025

Amendment to Quarterly Report (Form 10-Q/A)

November 17, 2025

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

November 11, 2025

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

October 30, 2025

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

October 23, 2025

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

October 21, 2025

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

September 4, 2025

iBio Announces Closing of $50 Million Public Offering

August 24, 2025

iBio Announces Pricing of $50 Million Public Offering

August 18, 2025

iBio Announces Proposed Public Offering

August 17, 2025

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

June 24, 2025

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

June 23, 2025

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

June 16, 2025

iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

May 5, 2025

iBio Reports Fiscal Third Quarter 2025 Financial Results

May 2, 2025

iBio Raises $6.2 Million Through Warrant Inducement Transaction

April 29, 2025

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

April 22, 2025

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

April 6, 2025

iBio Reports Fiscal Second Quarter 2025 Financial Results

February 9, 2025

iBio Announces New Investments from Board Members and Officers

January 12, 2025

iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio

January 6, 2025

Decks in 2025